Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07439796
PHASE1
A Study of ORN252 in Healthy Participants
Sponsor: Orna Therapeutics, Inc.
View on ClinicalTrials.gov
Summary
The purpose of this study is to assess the safety and tolerability of ORN252 in healthy adult participants.
Official title: A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORN252 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-03
Completion Date
2027-03
Last Updated
2026-03-19
Healthy Volunteers
Yes
Conditions
Interventions
BIOLOGICAL
ORN252
ORN252 is a lipid nanoparticle encapsulating a circular RNA encoding an anti-CD19 CAR protein.
Locations (1)
Nucleus Network
Herston, Queensland, Australia